TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05701813

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: INOSITOLS
Description: 4000 mg of myo-inositol and 300 mg of D-chiro-inositol. Once a day for 90 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: CELLULOSE
Description: 4.3 grams of cellulose once a day for 90 days.
Study: NCT06333730

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: inferior alveolar nerve block
Description: After informed consent, the needle will be inserted into the muco-buccal fold adjacent to the mandibular molars and advanced it towards the mandibular foramen, aiming slightly anteriorly and superiorly. Aspirating to check for blood or resistance, the needle will be repositioned if either was present. Once the needle will be correctly positioned, the dental practitioner will slowly inject 1.8-1.9 mL of the anesthetic solution.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mental nerve block
Description: After informed consent, the needle will be inserted into the buccal fold between the lower premolars. Aspirating to check for blood or resistance. Once needle is correctly positioned, 0.6-0.9 ml of the anesthetic solution will be deposited.
Study: NCT04856111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone
Description: Same as arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nintedanib
Description: Same as arm description
Study: NCT05405790

Intervention type: PROCEDURE
Intervention: thoracic endovascular aortic repair
Description: In The TEVAR procedure, we implant a stent graft into the diseased area of the thoracic artery, providing a route for the blood to flow within the stent graft and excluding the diseased aorta.
Study: NCT05001607

Intervention type: DEVICE
Group type: OTHER
Intervention: Bronchial Blocker
Description: Trial of four methods of pulmonary blockade; one novel method and three published methods.
Study: NCT05931536

Intervention type: OTHER
Intervention: Dietary fibre
Description: Habitual dietary consumption from a variety of foods will be assessed using 7-day food logs entered by the participant and assessed for accuracy by a dietitian.

Intervention type: OTHER
Intervention: Dietary fibre
Description: Habitual dietary consumption from a variety of foods will be assessed using 7-day food logs entered by the participant and assessed for accuracy by a dietitian.
Study: NCT04980027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine (U300)
Description: Pharmaceutical form:Solution for injection in a prefilled pen Route of administration: Subcutaneous
Study: NCT05622916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Ethanol Extract (Piper crocatum)
Description: Topical ethanol extract of red betel leaves (Piper crocatum) 30% with the details of formulation on detailed description section

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trichloroacetic Acid Topical
Description: Trichloroacetic acid topical 90%
Study: NCT04207281

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Raw Honey
Description: Canada #2 white raw honey (1.5 tablespoons) supplied by SweetHeart Pollinators (Janeil Enterprises, Eatonia, SK) administered for 7 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Raw Honey
Description: Canada #2 white raw honey (1.5 tablespoons) supplied by SweetHeart Pollinators (Janeil Enterprises, Eatonia, SK) administered for 7 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Comparator
Description: Honey comparator(1.5 tablespoons) administered for 7 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Honey comparator(1.5 tablespoons) administered for 7 days
Study: NCT05931536

Intervention type: OTHER
Intervention: Dietary fibre
Description: Habitual dietary consumption from a variety of foods will be assessed using 7-day food logs entered by the participant and assessed for accuracy by a dietitian.
Study: NCT04931368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix
Description: De-escalated induction treatment with R/HD-MTX and two courses of MATRix

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention: four courses of MATRix
Description: Patients receive four courses of MATRix as induction treatment.
Study: NCT05433467

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT-guided localization for micro hepatocellular carcinoma before surgical resection
Description: After preoperative preparation was completed, on the day of surgery, disposable pulmonary nodular localization needle (Ningbo Sonjiecang Biological Technology Co., LTD., Model: SS510-10) was used for the localization of micro hepatocellular carcinoma that could be found by preoperative CT enhancement or MRI. After the micro hepatocellular carcinoma was located under the guidance of CT, and then the patient was sent to the operating room. During the operation, the lesion was removed according to the tail line of the positioning needle and the position of the positioning needle.
Study: NCT05620589

Intervention type: DRUG
Intervention: Amoxicillin + Tetracycline + Bismuth + Esomeprazole
Description: Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Esomeprazole 40mg bid or Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Esomeprazole 40mg bid

Intervention type: DRUG
Intervention: Amoxicillin + Tetracycline + Bismuth + Vonoprazan
Description: Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth +Vonoprazan 20mg bid or Amoxicillin1000mg bid+ Tetracycline 500mg tid+ Bismuth + Vonoprazan 20mg bid

Intervention type: DRUG
Intervention: Amoxicillin + Tetracycline + Bismuth + Tegoprazan
Description: Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid or Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Tegopraza 50mg bid
Study: NCT05155332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1831169
Description: BI 1831169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1831169
Description: BI 1831169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1831169
Description: BI 1831169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1831169
Description: BI 1831169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1831169
Description: BI 1831169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1831169
Description: BI 1831169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1831169
Description: BI 1831169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-1 antibody
Description: anti-PD-1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-1 antibody
Description: anti-PD-1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-1 antibody
Description: anti-PD-1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-1 antibody
Description: anti-PD-1 antibody
Study: NCT06518031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: meditation
Description: meditation practices were administered by the meditation expert for 6 weeks, three times a week for 20 minutes each session, totaling 60 minutes per week
Study: NCT05623059

Intervention type: DRUG
Group type: OTHER
Intervention: Slow Release DHEA
Description: DHEA is a hormone produced by the body's adrenal gland. In drug form, it is available as an over-the-counter supplement that is available on the market without prescription.

Intervention type: DRUG
Group type: OTHER
Intervention: Slow Release DHEA
Description: DHEA is a hormone produced by the body's adrenal gland. In drug form, it is available as an over-the-counter supplement that is available on the market without prescription.
Study: NCT05735171

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GTR surgery
Description: Gross total resection of the enhancing tumor volume

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AI-guided surgery
Description: Supramarginal resection including high-risk areas of recurrence
Study: NCT06341686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir 480 MG
Description: Oral Letermovir for 84 days is effective in the prophylaxis of CMV infection in high-risk kidney transplant recipients. Oral Letermovir for 84 days, is associated with a lower incidence of CMV infection in high-risk high-risk kidney transplant recipients. In addition, the use of Letermovir is safe and associated with a low incidence of CMV syndrome or disease up to 6 months after after kidney transplantation. Finally, prophylaxis with Letermovir is associated with a lower incidence of discontinuation of immunosuppressive drugs, reducing the risk of of clinical and subclinical acute rejection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganciclovir
Description: The threshold for starting treatment with Ganciclovir is a CMV DNAemia \> 5,000 IU in a single measurement (CMV infection) measurement (CMV infection) OR any CMV DNAemia with any signs or symptoms associated with CMV (syndrome or disease).
Study: NCT01996462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram Oxalate Tablets
Study: NCT05435482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Participants will receive two small group meetings and two follow-up calls

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 testing kits
Description: Participants will receive two COVID-19 at-home antigen test kits.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COVID-19 testing kits
Description: Participants will receive two COVID-19 at-home antigen test kits.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instruction
Description: Participants will receive a written guide and a video clip guide to the test kit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instruction
Description: Participants will receive a written guide and a video clip guide to the test kit.
Study: NCT05192148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients
Description: On the day of inclusion, as part of the research, an additional blood sample will be taken (2 dry tubes of 7 ml each).
Study: NCT05716724

Intervention type: DRUG
Intervention: Semaglutide
Description: Participants will receive oral semaglutide with or without other OADs as per local label at the discretion of the treating physician and is clearly independent from the decision to include the participant in the study.
Study: NCT06507462

Intervention type: PROCEDURE
Intervention: prostate biopsy
Description: All patients were required to underwent transperineal prostate biopsy and have corresponding pathological diagnosis results.
Study: NCT05047718

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine Pfizer (3 doses)
Description: A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine Pfizer (2 doses)
Description: A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA Vaccine Moderna (3 doses)
Description: A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA Vaccine Moderna (2 doses)
Description: A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA Vaccine Moderna (1 dose)
Description: A longitudinal analysis of the immune response post COVID-19 vaccine will be performed with a close immunomonitoring
Study: NCT04730193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine, also known as Trimethylxanthine, will be purchased through the University of Oklahoma Health Sciences Pharmacy and formulated into capsule pills containing 100mg of active ingredient

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill will be formulated with a non active ingredient such as rice flour powder
Study: NCT05248126

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard patient education
Description: The comparator intervention is the usual therapeutic training for patients (ETP) cursus currently used in the General Pulmonology unit at the Arnaud De Villeneuve Hospital, Montpellier, France and approved by the French Regional Health Authority for the Occitanie Region \[Agence Régional de Santé Occitanie\].

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chatbot patient education
Description: The experimental intervention consists in providing the patient with access to a specific version of the Vik-Asthme chat bot for the duration of the study. Should the patient be unable to use or refuse to use the chatbot, the reasons for refusal will be documented and the patient will proceed with the comparator intervention.
Study: NCT02974777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAPT reduction
Description: Reduction of standard dose DAPT due to low platelet reactivity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAPT on-target
Description: Standard DAPT within the therapeutic window of platelet reactivity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAPT on-target
Description: Standard DAPT within the therapeutic window of platelet reactivity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAPT intensification
Description: Intensification of standard dose DAPT due to high platelet reactivity
Study: NCT05048498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEX-18a injection
Description: In Treatment phase 1, NEX-18a will be given as a single subcutaneous injection.~In Treatment phase 2, NEX-18a will be given as a single subcutaneous injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine Injection
Description: In Treatment phase 1, azacitidine will be administered once daily for four days. In Treatment phase 2, azacitidine will be administered once daily for three days.
Study: NCT06107868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-6306
Description: RP-6306 is a selective inhibitor of PKMYT1 kinase. RP-6306 is an investigational agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-6306
Description: RP-6306 is a selective inhibitor of PKMYT1 kinase. RP-6306 is an investigational agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is an antineoplastic agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is an antineoplastic agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is an antineoplastic agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is an antineoplastic agent.
Study: NCT04387500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab injection plus Inlyta treatment
Description: Combined Sintilimab injection and Inlyta treatment in FH-deficient RCC
Study: NCT06479213

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REACH Peer Coaching Program
Description: The REACH Peer Coaching Program consists of weekly coaching calls conducted over video teleconference. Coaches will use motivational interviewing to help participants formulate and work towards movement goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: REACH Mobile Health Application
Description: Participants will use the the REACH mobile health application to set weekly movement goals and log physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REACH Mobile Health Application
Description: Participants will use the the REACH mobile health application to set weekly movement goals and log physical activity.
Study: NCT05854407

Intervention type: OTHER
Group type: OTHER
Intervention: skim milk
Description: pasteurized or high-pasteurized skim milk

Intervention type: OTHER
Group type: OTHER
Intervention: skim milk
Description: pasteurized or high-pasteurized skim milk
Study: NCT05905627

Intervention type: BEHAVIORAL
Intervention: exercise
Description: intervention group

Intervention type: BEHAVIORAL
Intervention: exercise
Description: intervention group
Study: NCT05263674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapid sedation
Description: High-dose Propofol (bolus 3-5 g / kg, maintenance dose 5-10 mg / kg / hour) to - 5 on the Richmond agitation sedation scale (RASS) for 20 hours, and a single anti-epileptic drug should be added as adjunctive therapy. Addition of low-dose Midazolam (max. 0.1 mg / kg / h) is permitted if deep sedation (defined clinically by RASS -5) is not possible with Propofol alone.
Study: NCT05943366

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Keep-on-Keep-Up Nutrition (KOKU-Nut)
Description: Keep-on-Keep-Up (KOKU) is a free, tablet-based strength and balance exercise application that was soft launched in 2020 (https://kokuhealth.com/). KOKU is approved by the National Health Service (NHS) and Organisation for the Review of Care and Health Apps (ORCHA) as a lifestyle app and has been viewed positively by older adults after 6 weeks of independent use. KOKU-Nut is the latest development of this interactive platform and includes nutritional games based on the UK dietary guidelines to nudge older adults to improve their diet with a specific focus on protein, fibre and fluid.
Study: NCT05857761

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active repetitive transcranial magnetic stimulation (rTMS)
Description: Five sessions of active rTMS therapy will be distributed over 2 weeks (20 Hz, 2000 pulses, 90% resting motor threshold) will be delivered to left dorsolateral pre-frontal cortex (DLPFC) around 6 months post-trauma.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation (rTMS)
Description: Five sessions of sham rTMS therapy will be distributed over 2 weeks
Study: NCT06441318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povorcitinib
Description: Povorcitinib will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povorcitinib
Description: Povorcitinib will be administered at protocol defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered at protocol defined dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered at protocol defined dose.
Study: NCT05816772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endosequence Bio ceramic Sealer
Description: Brasseler,USA, a nano-particulate injectable premixed bioceramic sealer that contains Calcium Silicates, Calcium Phosphate, Calcium Hydroxide and Zirconium Oxide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sealapex Calcium hydroxide Based Sealer
Description: KERR Dental, an original eugenol-free root canal sealant based on calcium hydroxide.
Study: NCT06441318

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin will be administered at protocol defined dose.
Study: NCT04940338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromfenac Ophthalmic 0.09% Ophthalmic Solution
Description: topical bromfenac (0.9 mg/mL) 2x daily 7 days before the surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Ophthalmic
Description: topical dexamethasone (1 mg/mL) 2x daily 7 days before the surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: topical placebo (artificial tears substitute) 2x daily before the surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacoemulsification surgery (PHACO)
Description: About 0.1-0.2 mL of aqueous humor will be collected at the beginning of the cataract surgery (PHACO) through paracentesis, aqueous will then be transported in dry ice with a dedicated box to the laboratory and stored at -80C until the analysis. IL6 concentration will be analyzed with Human IL6 Quantikine Elisa kit (R\&D System).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacoemulsification surgery (PHACO)
Description: About 0.1-0.2 mL of aqueous humor will be collected at the beginning of the cataract surgery (PHACO) through paracentesis, aqueous will then be transported in dry ice with a dedicated box to the laboratory and stored at -80C until the analysis. IL6 concentration will be analyzed with Human IL6 Quantikine Elisa kit (R\&D System).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Phacoemulsification surgery (PHACO)
Description: About 0.1-0.2 mL of aqueous humor will be collected at the beginning of the cataract surgery (PHACO) through paracentesis, aqueous will then be transported in dry ice with a dedicated box to the laboratory and stored at -80C until the analysis. IL6 concentration will be analyzed with Human IL6 Quantikine Elisa kit (R\&D System).
Study: NCT06401070

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Plesterin
Description: The plaster used is a round plaster that resembles the shape of an acupuncture press needle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Press needle acupuncture
Description: Press needle acupuncture is a modality of acupuncture using tiny and very thin needles.
Study: NCT05732753

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness + Education in Neurophysiology of pain
Description: An experimental group (GE) that after an initial evaluation and with their consent, will be subjected to a program that includes an intervention based on Mindfulness and an 8-week Education intervention, one day a week with a duration of 120 minutes. The sessions will be divided into two parts, a part of 60' of Mindfulness and another of 60' of Education. In the Mindfulness part, formal Meditation practices and conscious movements based on yoga will be carried out. In the Education part, participants will be instructed in concepts related to the basic neurophysiology of pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness + Education in Neurophysiology of pain
Description: An experimental group (GE) that after an initial evaluation and with their consent, will be subjected to a program that includes an intervention based on Mindfulness and an 8-week Education intervention, one day a week with a duration of 120 minutes. The sessions will be divided into two parts, a part of 60' of Mindfulness and another of 60' of Education. In the Mindfulness part, formal Meditation practices and conscious movements based on yoga will be carried out. In the Education part, participants will be instructed in concepts related to the basic neurophysiology of pain.
Study: NCT06332196

Intervention type: OTHER
Group type: OTHER
Intervention: Analysis of biological sample and clinical data
Description: Analysis of biological sample and clinical data